Skip to main content

Table 1 Data analysis of included studies

From: Evaluation of efficacy and safety for Brucea javanica oil emulsion in the control of the malignant pleural effusions via thoracic perfusion

Study

N

Male

Female

Age

(average)

 

Histology of Lung cancer

Volume of

MPE(N)

Quality

of Life

End point

MPE

LAC

LSCC

SCLC

Others

Guo Y 2004 [13]

60

40

20

59.5

60

> 1000 ml

KPS

RR, DCR, AEs

Lei H 2006 [14]

61

58–79

61

31

9

> 1000 ml

KPS

RR, DCR, SI, AEs

Wang H 2007 [15]

70

45

25

26–81

70

42

7

13

8

Large(46)

Moderate(24)

KPS

RR, DCR, SI, AEs

Wu S 2009 [16]

123

86

37

39–75

123

> 1000 ml

KPS

RR, DCR, AEs

Fu X 2009 [17]

120

82

38

25–78

120

Large(88)

Moderate(32)

KPS

RR, DCR, AEs

Chen Y 2011 [18]

61

27

34

43–75

61

> 1000 ml

KPS

RR, DCR, AEs

Jia L 2011 [19]

70

38

32

39–85

70

> 1000 ml

KPS

RR, DCR, SI, AEs

Liu B 2012 [20]

64

31

33

36–77

64

46

13

5

0

Large(36)

Moderate(28)

KPS

RR, DCR, SI, AEs

Zhang J 2012 [21]

64

45

19

28–81

64

20

29

12

3

> 1000 ml

KPS

RR, DCR, SI, AEs

Zhang H 2013 [22]

64

52

12

33–86

64

39

11

14

0

> 1000 ml

KPS

RR, DCR, SI, AEs

Yang G 2014 [23]

94

94

> 1000 ml

KPS

RR, DCR, SI, AEs

Yang H 2014 [24]

64

42

22

38–72

64

19

24

13

8

> 1000 ml

KPS

RR, DCR, SI, AEs

Yue K 2016 [25]

111

57

53

110

70

19

21

> 1000 ml

KPS

RR, DCR, SI, AEs

Wang C 2016 [26]

60

34

26

40–74

60

11

17

32

> 1000 ml

KPS

RR, DCR, SI, AEs

  1. N number of patients, MPE malignant pleural effusion, LAC lung adenocarcinoma, LSCC lung squamous cell carcinoma, SCLC small cell lung cancer, KPS karnofsky physical status score, RR response rate, DCR disease control rate, SI symptom improvement, AEs adverse effects